Michael L Hancock
Overview
Explore the profile of Michael L Hancock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu E, Hancock M, Aronson W, Flaig T, Belkoff L, Tutrone R, et al.
Clin Genitourin Cancer
. 2020 Apr;
18(6):436-443.
PMID: 32321673
Introduction: Novel estrogen therapy has the potential to be efficacious, with a favorable adverse event profile, in castration-resistant prostate cancer (CRPC). We performed a phase 2 trial to assess the...
2.
Schweizer M, Hancock M, Getzenberg R, Yu E
Asian J Androl
. 2017 Nov;
20(4):405-406.
PMID: 29111538
No abstract available.
3.
Crawford J, Prado C, Johnston M, Gralla R, Taylor R, Hancock M, et al.
Curr Oncol Rep
. 2016 May;
18(6):37.
PMID: 27138015
Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be...
4.
Yu E, Getzenberg R, Coss C, Gittelman M, Keane T, Tutrone R, et al.
Eur Urol
. 2014 Jun;
67(2):334-41.
PMID: 24968970
Background: A need remains for new therapeutic approaches for men with advanced prostate cancer, particularly earlier in the disease course. Objective: To assess the ability of an oral selective estrogen...
5.
Coss C, Jones A, Hancock M, Steiner M, Dalton J
Asian J Androl
. 2014 Jan;
16(2):256-61.
PMID: 24407183
Several testosterone preparations are used in the treatment of hypogonadism in the ageing male. These therapies differ in their convenience, flexibility, regional availability and expense but share their pharmacokinetic basis...
6.
Park K, Dalton J, Narayanan R, Barbieri C, Hancock M, Bostwick D, et al.
J Clin Oncol
. 2013 Dec;
32(3):206-11.
PMID: 24297949
Purpose: High-grade prostatic intraepithelial neoplasia (HGPIN) is considered a precursor lesion of prostate cancer (PCa). The predictive value of ERG gene fusion in HGPIN for PCa was interrogated as a...
7.
Dobs A, Boccia R, Croot C, Gabrail N, Dalton J, Hancock M, et al.
Lancet Oncol
. 2013 Mar;
14(4):335-45.
PMID: 23499390
Background: Cancer-induced muscle wasting begins early in the course of a patient's malignant disease, resulting in declining physical function and other detrimental clinical consequences. This randomised, double-blind, placebo-controlled phase 2...
8.
Taneja S, Morton R, Barnette G, Sieber P, Hancock M, Steiner M
J Clin Oncol
. 2013 Jan;
31(5):523-9.
PMID: 23295793
Purpose: Prostate cancer (PCa) prevention remains an appealing strategy for the reduction of overtreatment and secondary adverse effects. We evaluated the efficacy of toremifene citrate 20 mg in PCa prevention...
9.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer
Smith M, Morton R, Barnette K, Sieber P, Malkowicz S, Rodriguez D, et al.
J Urol
. 2012 Dec;
189(1 Suppl):S45-50.
PMID: 23234631
Purpose: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men...
10.
Morgans A, Hancock M, Barnette K, Steiner M, Morton R, Smith M
J Urol
. 2012 Jan;
187(3):889-93.
PMID: 22245322
Purpose: Whether race influences bone loss and fracture risk during androgen deprivation therapy for prostate cancer is unknown. Using data from a prospective clinical trial we compared bone mineral density...